Clinical Trajectory and Pathophysiology of Paclitaxel-Induced Peripheral Neuropathy

Clinical Trajectory

Paclitaxel-induced peripheral neuropathy presents primarily as a sensory axonal neuropathy that typically begins during the first 2 months of treatment, with symptoms that tend to resolve between doses and improve over several months after treatment completion, though it can persist as a debilitating problem for years in some patients 1, 2
Symptoms typically occur during the first 2 months of treatment and progress during active chemotherapy 2
Unlike oxaliplatin-related symptoms, paclitaxel-induced neuropathy symptoms tend to resolve more between doses 1
Symptoms are not worsened, on average, in subsequent cycles 1
Primarily sensory neuropathy with a stocking-glove distribution that begins distally in fingers and toes and can progress proximally as the condition worsens 1
Paclitaxel-induced chronic neuropathy symptoms are more prominent in the lower extremities than upper extremities during treatment 1
Follows a symmetrical length-dependent pattern (dying back axonopathy) 2
Most common symptoms include numbness, tingling, and pain 1
Numbness and tingling appear earlier and are generally more prominent problems than pain 1
After completion of chemotherapy, paclitaxel neuropathy, on average, improves over the ensuing several months 1
Although neuropathy tends to improve over time, it can remain as a substantial debilitating problem in a subset of patients for years 1

Paclitaxel-induced neuropathy differs from oxaliplatin-induced neuropathy in several ways, including distribution pattern and recovery pattern 1, 2

Diagnosis can generally be made by clinical history 1
If a patient receiving paclitaxel develops new or worsening numbness, tingling, and/or pain in hands and/or feet without other explanations, the diagnosis is made 1
Neurologic physical examination may be abnormal 1
Neurologic tests such as electromyography (EMG) can be used but are not usually necessary 1

CIPN can markedly affect quality of life 1
May limit the amount of chemotherapy that can be given, potentially affecting cancer outcomes 1
Clinicians should assess and discuss the appropriateness of dose delaying, dose reduction, or stopping chemotherapy in patients who develop intolerable neuropathy and/or functional nerve impairment 1
For painful CIPN, duloxetine may be offered as treatment 1

Risk factors that may predispose to more severe neuropathy include diabetes mellitus, increasing age, concurrent exposure to other neurotoxic agents, pre-existing neuropathy, and conditions predisposing to neuropathy 2
Smoking appears to increase the risk of long-term prevalent paraesthesia 2

Paclitaxel causes an acute pain syndrome that typically develops within 1-3 days after administration and largely resolves within a week, according to the American Society of Clinical Oncology 3
This acute syndrome has been classically labeled as arthralgia/myalgia but is likely a form of acute neuropathy, as suggested by the American Society of Clinical Oncology 3

After completion of chemotherapy, paclitaxel neuropathy begins improving immediately, unlike oxaliplatin-induced neuropathy which may worsen for 2-6 months after treatment cessation, as reported by the American Society of Clinical Oncology 4, 5, 3
Most patients experience improvement in symptoms over several months following treatment cessation, with complete resolution occurring in some patients, according to the American Society of Clinical Oncology 4, 5, 3

For patients experiencing painful paclitaxel-induced neuropathy, duloxetine may be offered as treatment, as recommended by the American Society of Clinical Oncology 3, 6
A topical gel containing baclofen, amitriptyline HCL, and ketamine may be reasonable to try for selected patients with chemotherapy-induced peripheral neuropathy pain, though evidence is limited, as suggested by the American Society of Clinical Oncology 3
Emerging evidence suggests cryotherapy or compression therapy may help reduce paclitaxel-induced neuropathy, though more research is needed, according to the American Society of Clinical Oncology 7

Paclitaxel-induced neuropathy can be confused with other forms of neuropathic pain, but it has distinct pathophysiology and symptomatology, as noted by the American Society of Clinical Oncology 3
Monitoring for neuropathy should continue after treatment completion, as symptoms may persist or evolve, as recommended by the American Society of Clinical Oncology 4, 5, 3